Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 12, 2026

Consolidated Financial Results for the Three Months Ended September 30, 2026 (Japanese Accounting Standards)

Company name: TAUNS Laboratories, Inc.
Listing: Tokyo Stock Exchange
Securities code: 197A
URL: https://www.tauns.co.jp/
Representative: Masaki Nonaka, President and CEO
Contact person: Tomohiko Morita, Managing Executive Officer, General Manager, Administration Division
Telephone: +81-55-953-9590
Scheduled date of payment of cash dividends: —
The additional material of the Financial Results: Yes
The briefing session of the Financial Results: No

(Amounts less than one million yen are rounded down.)

1. Consolidated Financial Results for the Three Months Ended September 30, 2026（July 1, 2026 - September 30, 2026）

(1) Consolidated operating results

(Percent indications show percentage of changes from corresponding figures for the previous period)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
Three Months Ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	3,621	—	925	—	844	—	576	—
September 30, 2025	—	—	—	—	—	—	—	—

Note: Comprehensive Income 1st Quarter of FY 2027: ¥544 million (—%) 1st Quarter of FY2026: ¥— million (—%)

	Basic earnings per share	Diluted earnings per share
Three Months Ended	Yen	Yen
September 30, 2026	5.40	5.35
September 30, 2025	—	—

Note: No consolidated financial results for the three months ended September 30, 2025 being prepared, the increase/decrease ratio for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 is not presented.

(2) Consolidated financial position

	Total assets	Net assets	Net assets as a percentage of total assets
	Millions of yen	Millions of yen	%
FY2027 1st quarter	43,207	18,207	42.1
FY2026	—	—	—

Reference: Net assets excluding share subscription rights: 18,206 million yen as of September 30, 2026
— as of June 30, 2026

Note: As consolidated financial statements were not prepared in the first quarter of the fiscal year ended June 30, 2026, corresponding figures are not presented.

2. Dividends

	Annual cash dividends per share				
	At 1st quarter end	At 2nd quarter end	At 3rd quarter end	At fiscal year end	Total
	yen	yen	yen	yen	yen
FY2026	—	14.00	—	14.00	28.00
FY2027	—				
FY2027 (Forecast)		14.50	—	14.50	29.00

Note: Changes in dividends forecast from the latest disclosure: No

3. Forecast of consolidated operating results for FY2027 (July 1, 2026 - June 30, 2027)

(Indications show percentage of changes from corresponding figures for the previous period)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
FY2027	16,730	16.4	4,374	4.1	4,026	1.9	2,965	(46.0)	27.80

Note Changes in forecast of operating results for FY 2027 from the latest disclosure: No
Forecast for consolidated operating results for FY2027 1st half is not prepared.

※ Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (CLAIRVO TECHNOLOGIES, Inc.) Excluded: None

(2) Adoption of specific accounting policies for quarterly consolidated financial statements: Yes

Note: For details, please refer to page 7 of the accompanying materials, "2. Quarterly Consolidated Financial Statements and Principal Notes, (3) Notes to Quarterly Consolidated Financial Statements (Notes on Accounting Treatments Specific to the Preparation of Quarterly Financial Statements)."

(3) Changes in accounting policies, accounting estimation change and restatement

① Changes in accounting policies due to the revision of the accounting standards：None

② Changes in accounting policies except for those in ① ：Yes

③ Changes due to accounting estimation change：None

④ Restatement：None

Note: For details, please refer to page 7 of the accompanying materials, "2. Quarterly Consolidated Financial Statements and Principal Notes, (3) Notes to Quarterly Consolidated Financial Statements (Notes on Changes in Accounting Policies)."

(4) Number of shares issued (common shares)

① Number of shares issued at the fiscal year end (including treasury stocks)	FY2027 1st quarter	106,813,093 shares	FY2026	106,691,686 shares
② Number of treasury stocks at the fiscal year end	FY2027 1st quarter	— shares	FY2026	— shares
③ The average number of shares issued during the fiscal year	FY2027 1st quarter	106,762,049 shares	FY2026 1st quarter	103,178,998 shares

※ Review by external auditor: None

※ Explanation regarding the appropriate use of forecast of business results

The financial forecast is based on judgments and estimates that have been made on the basis of currently available information. By nature, such financial forecast is subject to uncertainty and risk. Therefore, you are advised that the final results might be significantly different from the aforementioned forecast due to changes in economic environments related to our business, market trends and exchange rate, etc. Please refer to page 2 of the accompanying materials, "1. Overview of Operating Results, etc. (3) Explanation of Forward-looking Information, Including Consolidated Earnings Forecasts," for the assumptions underlying the earnings forecasts and notes on the use of such forecasts.

○Table of content of material

1. Overview of the Operating Results, etc. …… 2
(1) Overview of Business Performance for the Current Quarter …… 2
(2) Overview of Financial Position for the Current Quarter …… 2
(3) Explanation of Forward-looking Information, Including Consolidated Earnings Forecasts …… 2
2. Quarterly Consolidated Financial Statements …… 3
(1) Quarterly Consolidated Balance sheet …… 3
(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income …… 5
Quarterly Consolidated Statement of Income …… 5
Quarterly Consolidated Statement of Comprehensive Income…… 6
(3) Notes to Quarterly Consolidated Financial Statements …… 7
Notes on Accounting Treatments Specific to the Preparation of Quarterly Financial Statements …… 7
Notes on Changes in Accounting Policies …… 7
Notes to business segments and related information …… 7
Notes to significant changes in shareholders' equity …… 7
Notes to events and conditions which indicate there could be substantial doubt about going concern assumption ……. 7
Notes to quarterly consolidated cash flow statements …… 7

1. Overview of the Operating Results, etc.

(1) Overview of Business Performance for the Current quarter

As the Company prepared consolidated financial statements for the first time from the first quarter of the current fiscal year, no year-on-year comparison with the corresponding period of the previous fiscal year has been presented.

Regarding the business environment of the in vitro diagnostics industry during the first quarter of the fiscal year ending June 30, 2027 (July 1, 2026 to September 30, 2026), the spread of COVID-19 remained at a lower level than in the same period of the previous year, while the influenza season began earlier than usual, around the end of August. In addition, the inventory adjustment observed in the corresponding period of the previous year was resolved, and supply-demand conditions returned to normal.

As a result, for the first quarter of the fiscal year, net sales amounted to ¥3,621 million, operating income to ¥925 million, ordinary income to ¥844 million, and net income attributable to owners of parent to ¥576 million.

The operating results by segment were as follows:

(In Vitro Diagnostics Business)

In the In Vitro Diagnostics Business, although the spread of COVID-19 remained at a lower level than in the same period of the previous year, a certain number of infections continued to occur. In addition, as the influenza season began earlier than usual, around the end of August, the Group responded to demand for influenza test kits and COVID-19/influenza combination test kits. As a result, net sales in this segment amounted to ¥3,613 million and operating profit amounted to ¥989 million for the first quarter of the fiscal year.

(Other Business)

In the Other Business segment, the Group promoted sales activities aimed at expanding sales of medical AI-related products, while making preparations for the launch of new products, primarily in the cardiovascular field, and strengthening its business foundation. As a result, net sales in this segment amounted to ¥8 million and operating loss amounted to ¥63 million for the first quarter of the fiscal year.

(2) Overview of Financial Position for the Current Quarter

The financial position as of September 30, 2026 was as follows. As the Company prepared consolidated financial statements for the first time from the first quarter of the current fiscal year, no comparison with the end of the previous fiscal year has been presented.

1. Assets

Total assets as of September 30, 2026 amounted to ¥43,207 million.

Current assets amounted to ¥15,940 million, consisting primarily of cash and deposits of ¥3,726 million, accounts receivable - trade of ¥4,384 million, merchandise and finished goods of ¥2,445 million, and work in process of ¥3,009 million.

Fixed assets amounted to ¥27,266 million, consisting primarily of property, plant and equipment of ¥15,140 million (including buildings and structures of ¥9,900 million, machinery, equipment and vehicles of ¥4,708 million, and land of ¥1,734 million), intangible fixed assets of ¥3,511 million (including customer related assets of ¥2,215 million and software of ¥651 million), and investments and other assets of ¥8,614 million (including investment securities of ¥8,578 million).

2. Liabilities

Total liabilities as of September 30, 2026 amounted to ¥24,999 million.

Current liabilities amounted to ¥12,882 million, consisting primarily of accounts payable - trade of ¥429 million, short-term borrowings of ¥7,500 million, and current portion of long-term borrowings of ¥2,247 million.

Long-term liabilities amounted to ¥12,116 million, consisting primarily of long-term borrowings of ¥10,116 million and deferred tax liabilities of ¥1,640 million.

3. Net Assets

Total net assets as of September 30, 2026 amounted to ¥18,207 million.

Major components included shareholders' equity of ¥18,155 million, consisting of common stock of ¥404 million, capital surplus of ¥2,887 million, and retained earnings of ¥14,862 million, as well as accumulated other comprehensive income of ¥51 million and share subscription rights of ¥1 million.

As a result, the equity ratio was 42.1%.

(3) Explanation of Forward-looking Information, Including Consolidated Earnings Forecasts

There have been no changes to the full-year consolidated earnings forecast for the fiscal year ending June 30, 2027, which was announced on August 13, 2026.

2. Quarterly Consolidated Financial Statements and Principal Notes

(1) Quarterly Consolidated Balance Sheet

(Unit: thousands of yen)

	Current first quarter (As of September 30, 2026)
Assets	
Current assets	
Cash on hand and in banks	3,726,755
Accounts receivable – trade	4,384,917
Merchandise and finished goods	2,445,574
Work in process	3,009,665
Raw materials and supplies	1,076,324
Other	1,297,244
Total current assets	15,940,482
Fixed assets	
Property, plant and equipment	
Buildings and structures	9,900,702
Machinery, equipment and vehicles	4,708,787
Land	1,734,634
Other	1,608,113
Accumulated depreciation and impairment loss	(2,811,300)
Total property, plant and equipment	15,140,937
Intangible fixed assets	
Software	651,979
Customer related assets	2,215,200
Technology related assets	472,466
Other	171,710
Total of intangible fixed assets	3,511,357
Investments and other assets	
Investment securities	8,578,231
Other	36,034
Total investments and other assets	8,614,266
Total fixed assets	27,266,561
Total assets	43,207,044

(Unit: thousands of yen)

	Current first quarter (As of September 30, 2026)
Liabilities	
Current liabilities	
Accounts payable – trade	429,310
Short-term borrowings	7,500,000
Current portion of long-term borrowings	2,247,639
Accrued income taxes	287,128
Allowance for bonuses	154,604
Other	2,263,813
Total current liabilities	12,882,496
Long-term liabilities	
Long-term borrowings	10,116,643
Deferred tax liabilities	1,640,827
Net defined benefit liability	347,165
Asset retirement obligations	12,000
Total long-term liabilities	12,116,636
Total liabilities	24,999,133
Net assets	
Shareholders' equity	
Common stock	404,392
Deposits for subscriptions rights to common stocks	801
Capital surplus	2,887,692
Retained earnings	14,862,522
Total shareholders' equity	18,155,409
Accumulated other comprehensive Income	
Net unrealized gains (losses) on available-for-sale securities	54,329
Remeasurements of defined benefit plans	(2,916)
Accumulated other comprehensive income	51,412
Share subscription rights	1,088
Total net assets	18,207,910
Total liabilities and net assets	43,207,044

(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income

(Quarterly Consolidated Statement of Income)

(Unit: thousands of yen)

	Current first quarter (From July 1, 2026 To September 30, 2026)
Net sales	3,621,804
Cost of sales	1,358,036
Gross profit	2,263,767
Selling, general and administrative expenses	1,337,941
Operating income	925,826
Non-operating income	
Interest income	6,977
Dividends income	161
Miscellaneous income	264
Total non-operating income	7,403
Non-operating expenses	
Interest expenses	88,627
Miscellaneous expenses	481
Total non-operating expenses	89,109
Ordinary income	844,120
Special gains	
Gain on sales of fixed assets	1,322
Total special gains	1,322
Special losses	
Loss on disposal of fixed assets	0
Total special losses	0
Income before income taxes	845,442
Income taxes	268,837
Net income	576,605
Net income attributable to owners of parent	576,605

(Quarterly Consolidated Statement of Comprehensive Income)

(Unit: thousands of yen)

	Current first quarter (From July 1, 2026 To September 30, 2026)
Net income	576,605
Other comprehensive Income	
Net unrealized gains (losses) on available-for-sale securities	△32,302
Remeasurements of defined benefit plans	153
Total other comprehensive income	△32,149
Comprehensive Income	544,455
Comprehensive income attributable to:	
Owners of parent	544,455
Non-controlling Interests	—

(3) Notes to Quarterly Consolidated Financial Statements

(Notes on Accounting Treatments Specific to the Preparation of Quarterly Financial Statements)

(Calculation of Tax Expense)

Income taxes are calculated by reasonably estimating the effective tax rate after the application of tax-effect accounting to profit before income taxes for the consolidated fiscal year, including the first quarter under review, and applying such estimated effective tax rate to quarterly profit before income taxes.

(Notes on Changes in Accounting Policies)

(Change in the Method of Calculating Retirement Benefit Obligations)

Effective from the first quarter of the current consolidated fiscal year, the Company changed the method of calculating its retirement benefit obligations from the simplified method to the actuarial method. This change was made based on the steady progress in increasing the workforce in line with the Company's hiring plan, and because the Company determined that adopting the actuarial method would improve the accuracy of estimating retirement benefit obligations and enable retirement benefit expenses to be more appropriately reflected in periodic earnings. This change in accounting policy has been applied retrospectively. As a result of reflecting the cumulative effect of the change in the opening balance of net assets for the current consolidated fiscal year, retirement benefit obligations increased by ¥119,265 thousand, deferred tax liabilities decreased by ¥39,686 thousand, retained earnings decreased by ¥79,508 thousand, and remeasurements of defined benefit plans decreased by ¥3,070 thousand as of the beginning of the current consolidated fiscal year.

(Notes to Business Segments and Related Information)

【Business Segments Information】

1. Information on Net Sales and Profit (Loss) by Reportable Segment

For the First Quarter of the Fiscal Year Ending June 30, 2027 (From July 1, 2026 to September 30, 2026)

(Unit: thousands of yen)

	Reportable Segments	Other (Note 1)	Total	Adjustments	Amounts in the Quarterly Consolidated Financial Statements (Note 2)
	In Vitro Diagnostics Business				
Net Sales					
Sales to External Customers	3,613,251	8,553	3,621,804	—	3,621,804
Intersegment Sales or Transfers	—	—	—	—	—
Segment Profit (Loss)	989,679	(63,852)	925,826	—	925,826

Notes:

1. The "Other" segment includes business segments that are not included in the reportable segments.
2. Segment profit (loss) is reconciled to operating income presented in the quarterly consolidated statement of income.

2. Changes in Reportable Segments

The Group had previously consisted of a single reportable segment, the In Vitro Diagnostics Business. As CLAIRVO TECHNOLOGIES, Inc. became a consolidated subsidiary, segment information has been disclosed under a newly established "Other" segment from the first quarter of the current consolidated fiscal year.

(Notes to significant changes in shareholders' equity)

None

(Notes to events and conditions which indicate there could be substantial doubt about going concern assumption)

None

(Notes to quarterly cash flow consolidated statements)

Quarterly cash flow statements are not prepared for the current first quarter. The amount of depreciation including both tangible assets and intangible assets for the current first quarter is as follows:

	Current first quarter (From July 1, 2026 To September 30, 2026)
Depreciation	402,631 thousands of yen